Adaptive Biotechnologies vs Ionis Pharmaceuticals
Adaptive Biotechnologies (ADPT), health care, and Ionis Pharmaceuticals (IONS), health care, side by side on market value, valuation, margins, balance sheet and price change. Higher and lower are marked; neither is called better.
Adaptive Biotechnologies is worth $4.6B on the stock market and Ionis Pharmaceuticals $4.5B: Adaptive Biotechnologies is valued at 3% more. Adaptive Biotechnologies's operating margin in its latest fiscal year was -20.6% and Ionis Pharmaceuticals's -40.4%. Over the past year Adaptive Biotechnologies's share price has moved +103% and Ionis Pharmaceuticals's -62.4%.
Key facts
- Adaptive Biotechnologies market value
- $4.6B
- Ionis Pharmaceuticals market value
- $4.5B
- Adaptive Biotechnologies revenue
- $277MFY to 2025-12-31
- Ionis Pharmaceuticals revenue
- $943.7MFY to 2025-12-31
- Superinvestors holding both
- 1
Market values as of .
| Measure | Adaptive Biotechnologies | Ionis Pharmaceuticals |
|---|---|---|
| Sector | Health Care | Health Care |
| Country | ||
| Fiscal year ends | 2025-12-31 | 2025-12-31 |
| Size | ||
| Market cap | $4.6Bhigher | $4.5Blower |
| Revenue | $277Mlower | $943.7Mhigher |
| Earnings | -$59.5Mhigher | -$381.4Mlower |
| Employees | 624lower | 1,485higher |
| Total assets | $512.7Mlower | $3.5Bhigher |
| Valuation | ||
| P/E | — | — |
| P/S | 16.7higher | 4.8lower |
| P/B | 26.1higher | 11.4lower |
| Dividend yield | 0.00% | 0.00% |
| Profitability | ||
| Operating margin | -20.6%higher | -40.4%lower |
| Balance sheet | ||
| Net assets | $218.8Mlower | $489.1Mhigher |
| Total liabilities | $287.7Mlower | $3Bhigher |
| Total debt | $131.2Mlower | $1.8Bhigher |
| Cash on hand | $70.5Mlower | $372.3Mhigher |
| Price change | ||
| Today | +2.22%higher | -3.75%lower |
| 1 year | +103%higher | -62.4%lower |
Market value, P/E, P/B, dividend yield and price changes are from live quotes (Yahoo Finance; prices may be delayed 15 minutes or more). Revenue, earnings, operating margin and the balance-sheet figures are from each company's latest annual report filed with the SEC (collected 2026-11-12); a company that reports in another currency is converted to US dollars at the exchange rate of that day. P/S sets today's market value against the latest fiscal year's revenue. “Higher” and “lower” compare the two numbers only; a higher P/E or more debt is not better. Dividend yield and P/B are shown only for companies based in the US. A dash means no figure is on file.
Which superinvestors hold them
From each tracked investor's latest 13F filing. A 13F lists long positions in US-listed shares at a quarter end, filed up to 45 days later.
Both (1)
- Cathie Wood0.3% / 0.2%
Adaptive Biotechnologies only (2)
- Andreas Halvorsen1.8%
- Polen Capital team<0.1%
Ionis Pharmaceuticals only (3)
Percentages are each holding's share of that investor's reported portfolio (under "Both": Adaptive Biotechnologies / Ionis Pharmaceuticals). Who owns ADPT · Who owns IONS
More on Adaptive Biotechnologies
Further comparisons
Adaptive Biotechnologies against its closest peers
Ionis Pharmaceuticals against its closest peers
Learn
Questions and answers
Which is bigger, Adaptive Biotechnologies or Ionis Pharmaceuticals?
By market value, Adaptive Biotechnologies is the larger: $4.6B against $4.5B for Ionis Pharmaceuticals. By revenue in its latest fiscal year, Ionis Pharmaceuticals is the larger: $943.7M against $277M for Adaptive Biotechnologies.
Which has the higher operating margin?
Adaptive Biotechnologies: -20.6%, against -40.4% for Ionis Pharmaceuticals. Operating margin is operating income as a share of revenue in the latest fiscal year.
Which has the higher dividend yield?
Neither: both stand at 0.00%. Dividend yield is the last twelve months' dividends as a share of today's share price.
Which has more debt?
Ionis Pharmaceuticals: $1.8B, against $131.2M for Adaptive Biotechnologies. Total debt is borrowings at the end of the latest fiscal year, as each company reported it; it is not set against cash here.
Which superinvestors own both Adaptive Biotechnologies and Ionis Pharmaceuticals?
In their latest 13F filings, Cathie Wood holds both.
Cite this page
Funkfolio, “Adaptive Biotechnologies vs Ionis Pharmaceuticals”, data as of 18 November 2026. https://funkfolio.com/compare/adpt-vs-ions
Underlying data: Yahoo Finance quotes; SEC annual reports collected 2026-11-12; 13F filings.